EA201592301A1 - Бициклическое азотсодержащее ароматическое гетероциклическое амидное соединение - Google Patents
Бициклическое азотсодержащее ароматическое гетероциклическое амидное соединениеInfo
- Publication number
- EA201592301A1 EA201592301A1 EA201592301A EA201592301A EA201592301A1 EA 201592301 A1 EA201592301 A1 EA 201592301A1 EA 201592301 A EA201592301 A EA 201592301A EA 201592301 A EA201592301 A EA 201592301A EA 201592301 A1 EA201592301 A1 EA 201592301A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- breast cancer
- mct4
- expressed
- compound
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
Abstract
Предоставлено соединение, которое является полезным в качестве средства для лечения рака молочной железы. В результате тщательного изучения соединения, имеющего ингибирующий эффект в отношении Комплекса I и эффект активации АМРК, авторы настоящего изобретения обнаружили, что бициклическое азотсодержащее ароматическое гетероциклическое амидное соединение по настоящему изобретению имеет превосходный ингибирующий эффект в отношении Комплекса I и эффект активации АМРК, кроме того, имеет ингибирующий эффект в отношении пролиферации клеток касательно не только клеточных линий рака молочной железы с положительным мутационным статусом в гене PIK3CA человека, где МСТ4 не экспрессируется, но и клеточных линий рака молочной железы человека, которые не имеют мутацию в гене PIK3CA, где МСТ4 не экспрессируется, и проявляет противоопухолевый эффект в клетке MDA-MB-453 клеточной линии рака молочной железы с положительным мутационным статусом в гене PIK3CA человека у мыши-носителя гена рака, где МСТ4 не экспрессируется, в результате чего настоящее изобретение было доведено до завершения. Бициклическое азотсодержащее ароматическое гетероциклическое амидное соединение по настоящему изобретению может быть использовано в качестве средства для лечения рака молочной железы, в частности, рака молочной железы, где МСТ4 не экспрессируется, и из числа прочих, рака молочной железы с положительным мутационным статусом в гене PIK3CA человека, где МСТ4 не экспрессируется.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013122180 | 2013-06-10 | ||
| PCT/JP2014/065181 WO2014199933A1 (ja) | 2013-06-10 | 2014-06-09 | 二環式含窒素芳香族ヘテロ環アミド化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201592301A1 true EA201592301A1 (ru) | 2016-05-31 |
| EA028545B1 EA028545B1 (ru) | 2017-11-30 |
Family
ID=52022229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201592301A EA028545B1 (ru) | 2013-06-10 | 2014-06-09 | Бициклическое азотсодержащее ароматическое гетероциклическое амидное соединение |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9428501B2 (ru) |
| EP (1) | EP3009424B1 (ru) |
| JP (1) | JP5924453B2 (ru) |
| KR (1) | KR20160018686A (ru) |
| CN (1) | CN105308024B (ru) |
| AR (1) | AR096552A1 (ru) |
| AU (1) | AU2014279240A1 (ru) |
| BR (1) | BR112015030248A2 (ru) |
| CA (1) | CA2914982A1 (ru) |
| EA (1) | EA028545B1 (ru) |
| ES (1) | ES2661259T3 (ru) |
| HK (1) | HK1220446A1 (ru) |
| IL (1) | IL242997A (ru) |
| MX (1) | MX2015016965A (ru) |
| PH (1) | PH12015502744A1 (ru) |
| PL (1) | PL3009424T3 (ru) |
| PT (1) | PT3009424T (ru) |
| SA (1) | SA515370253B1 (ru) |
| SG (1) | SG11201510125WA (ru) |
| TW (1) | TW201536771A (ru) |
| WO (1) | WO2014199933A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016068099A1 (ja) * | 2014-10-28 | 2016-05-06 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有する複素環誘導体 |
| MA41158A (fr) * | 2014-12-09 | 2017-10-17 | Astellas Pharma Inc | Composition pharmaceutique comprenant un composé d'amide hétérocyclique aromatique contenat de l'azote bicyclique en tant que principe actif |
| MA41157A (fr) * | 2014-12-09 | 2017-10-17 | Astellas Pharma Inc | Composition pharmaceutique comprenant un composé d'amide hétérocyclique aromatique contenant de l'azote bicyclique en tant que composant actif |
| KR20170088880A (ko) * | 2014-12-09 | 2017-08-02 | 아스테라스 세이야쿠 가부시키가이샤 | 이환식 함질소 방향족 헤테로환 아미드 화합물을 유효 성분으로 하는 의약 조성물 |
| WO2017196936A1 (en) * | 2016-05-12 | 2017-11-16 | Regents Of The University Of Minnesota | Indole and indazole cyanocinnamate compounds and therapeutic uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932314A1 (de) * | 1999-07-10 | 2001-01-11 | Merck Patent Gmbh | Benzofuranderivate |
| WO2002020008A1 (en) | 2000-09-06 | 2002-03-14 | The Scripps Research Institute | Inhibitors of nadh:ubiquinone oxidoreductase |
| KR101280333B1 (ko) * | 2006-03-28 | 2013-07-02 | 하이 포인트 파마슈티칼스, 엘엘씨 | 히스타민 ｈ３ 수용체 활성을 갖는 벤조티아졸 |
| US7432255B2 (en) * | 2006-05-16 | 2008-10-07 | Hoffmann-La Roche Inc. | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives |
| WO2009082667A1 (en) * | 2007-12-21 | 2009-07-02 | 3M Innovative Properties Company | Microbiological systems and methods of fluid sample analysis |
| AU2008339572B2 (en) * | 2007-12-21 | 2012-05-10 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
| JP5658138B2 (ja) * | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
| AU2011283684B2 (en) * | 2010-07-29 | 2015-08-27 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocyclic compounds and methods for using the same |
| WO2013116491A1 (en) | 2012-02-01 | 2013-08-08 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using them |
-
2014
- 2014-06-09 SG SG11201510125WA patent/SG11201510125WA/en unknown
- 2014-06-09 AR ARP140102215A patent/AR096552A1/es unknown
- 2014-06-09 KR KR1020167000279A patent/KR20160018686A/ko not_active Application Discontinuation
- 2014-06-09 CN CN201480033143.0A patent/CN105308024B/zh active Active
- 2014-06-09 CA CA2914982A patent/CA2914982A1/en not_active Abandoned
- 2014-06-09 EP EP14810281.7A patent/EP3009424B1/en active Active
- 2014-06-09 PT PT148102817T patent/PT3009424T/pt unknown
- 2014-06-09 AU AU2014279240A patent/AU2014279240A1/en not_active Abandoned
- 2014-06-09 PL PL14810281T patent/PL3009424T3/pl unknown
- 2014-06-09 TW TW103119885A patent/TW201536771A/zh unknown
- 2014-06-09 ES ES14810281.7T patent/ES2661259T3/es active Active
- 2014-06-09 WO PCT/JP2014/065181 patent/WO2014199933A1/ja active Application Filing
- 2014-06-09 US US14/418,672 patent/US9428501B2/en active Active
- 2014-06-09 EA EA201592301A patent/EA028545B1/ru not_active IP Right Cessation
- 2014-06-09 JP JP2015522759A patent/JP5924453B2/ja not_active Expired - Fee Related
- 2014-06-09 BR BR112015030248A patent/BR112015030248A2/pt active Search and Examination
- 2014-06-09 MX MX2015016965A patent/MX2015016965A/es active IP Right Grant
-
2015
- 2015-12-09 PH PH12015502744A patent/PH12015502744A1/en unknown
- 2015-12-09 SA SA515370253A patent/SA515370253B1/ar unknown
- 2015-12-09 IL IL242997A patent/IL242997A/en not_active IP Right Cessation
-
2016
- 2016-07-15 HK HK16108380.3A patent/HK1220446A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2014199933A1 (ja) | 2017-02-23 |
| TW201536771A (zh) | 2015-10-01 |
| EP3009424B1 (en) | 2017-12-20 |
| CA2914982A1 (en) | 2014-12-18 |
| ES2661259T3 (es) | 2018-03-28 |
| US20150266869A1 (en) | 2015-09-24 |
| PL3009424T3 (pl) | 2018-03-30 |
| EP3009424A4 (en) | 2016-11-30 |
| HK1220446A1 (zh) | 2017-05-05 |
| US9428501B2 (en) | 2016-08-30 |
| PT3009424T (pt) | 2018-01-16 |
| CN105308024B (zh) | 2017-10-27 |
| MX2015016965A (es) | 2016-04-25 |
| EP3009424A1 (en) | 2016-04-20 |
| IL242997A (en) | 2017-04-30 |
| JP5924453B2 (ja) | 2016-05-25 |
| SG11201510125WA (en) | 2016-01-28 |
| BR112015030248A2 (pt) | 2017-07-25 |
| AR096552A1 (es) | 2016-01-13 |
| SA515370253B1 (ar) | 2017-03-06 |
| KR20160018686A (ko) | 2016-02-17 |
| EA028545B1 (ru) | 2017-11-30 |
| WO2014199933A1 (ja) | 2014-12-18 |
| CN105308024A (zh) | 2016-02-03 |
| AU2014279240A1 (en) | 2016-01-07 |
| PH12015502744A1 (en) | 2016-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502810A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| CY1120035T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
| CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
| CL2016000918A1 (es) | Compuestos derivados de pirimidin amidas con actividad inhibidora del factor de crecimiento fgfr (fgfr4 y fgf19); composición farmacéutica que los comprende y uso en el tratamiento del carcinoma hepatocelular. | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
| MY170904A (en) | Ret inhibitor | |
| MX362215B (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
| IN2015DN03795A (ru) | ||
| EA201592301A1 (ru) | Бициклическое азотсодержащее ароматическое гетероциклическое амидное соединение | |
| EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2017006015A (es) | Composiciones para usar en el tratamiento de cancer renal. | |
| MX2014011583A (es) | Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. | |
| EA201591399A1 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| EA201490800A1 (ru) | Способ ингибирования деубиквитинирующей активности | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| PH12017500121A1 (en) | Tablet formulation of a c-met inhibitor | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| BR112015013260A2 (pt) | uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas | |
| MX2015013936A (es) | Compuestos de pirimidina condensada sustituida. | |
| EA201792346A1 (ru) | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc) | |
| SG10201900954SA (en) | Heterocycles as Modulators of Kinase Activity | |
| PH12019550033A1 (en) | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan | |
| PH12018502571A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |